{"content":[{"text":"Trying to Settle Ongoing Dispute, HUPO’s IAB <br>Finds 2D Gel Exp...","bbox":{"left":0.0,"top":-0.001958,"width":0.48325300000000004,"height":0.016877}},{"text":"http://www.proteomonitor.com/issues/7_44/features/143404-1.html?type=pf","bbox":{"left":0.497752,"top":-0.001958,"width":0.50169,"height":0.016877}},{"text":"technology, educate the proteomics community about new research and tools, and to help develop standards in \n research methodology and techniques [See PM 11/02/06 and 04/26/07].","bbox":{"left":0.068333,"top":0.043347,"width":0.8270050000000001,"height":0.032647999999999996}},{"text":"Today, the group consists of 22 companies, including proteomic alpha males Applied Biosystems, Thermo Fisher \n Scientific, and Waters, as well as smaller shops such as Promega, Zeptosens, and Protein Forest.","bbox":{"left":0.068334,"top":0.087816,"width":0.8381580000000001,"height":0.032647999999999996}},{"text":"“The minute you start \n tweaking, you get different \n results.”","bbox":{"left":0.091863,"top":0.168358,"width":0.241553,"height":0.061744999999999994}},{"text":"According to Nonlinear’s Dracup, the 2D gel study comes at a time when the credibility of proteomics as a research \n field has been suffering. Gone is the irrational exuberance that had some believing proteomics would be the magic \n bullet to cure cancer, decipher Alzheimer’s disease, and unravel the mysteries of myriad other diseases.","bbox":{"left":0.068334,"top":0.263043,"width":0.853201,"height":0.04741999999999996}},{"text":"In its place is the sobering reality that the field is painfully complicated and it may be years before significantly \n meaningful results can be achieved.","bbox":{"left":0.068334,"top":0.32236,"width":0.811479,"height":0.032648999999999984}},{"text":"“Proteomics has gotten a bit of bad press and people feel that maybe it hasn’t delivered on its promise, and some \n funders, pharmaceutical companies, and the like have been losing a little bit of faith in the discipline,” Dracup said.","bbox":{"left":0.068334,"top":0.366906,"width":0.845857,"height":0.032647999999999955}},{"text":"One of the main bottlenecks to progress in the field has been the lack of reproducibility of results, on any technology \n platform.","bbox":{"left":0.068334,"top":0.411375,"width":0.8601719999999999,"height":0.03264800000000001}},{"text":"“From my point of view, the ability to reproduce experiments in different labs is a fundamental scientific discipline, \n and it’s one that heretofore has been perceived to not be feasible in proteomics,” Dracup said. “Now with this \n reproducibility test that we’ve done, we’ve actually proved that it is feasible and we’ve also started to show … that \n when you can do cross-lab analyses, you can actually get an awful lot more out of your experiment,” he said.","bbox":{"left":0.068334,"top":0.45592,"width":0.840174,"height":0.062271000000000076}},{"text":"The next step in the study is a repeat test on a larger scale that could involve as many as 1,000 laboratories, van \n Oostrum said. Such a study would include inexperienced labs and any success they have in reproducing \n experiments would provide greater proof of principle.","bbox":{"left":0.068334,"top":0.530088,"width":0.836019,"height":0.04749700000000001}},{"text":"The five labs that participated in the first test were “high profile and it could be suggested that this success was \n more due to the skills of the participants than the capabilities of the technologies,” according to the minutes from the \n October meeting of the IAB.","bbox":{"left":0.068334,"top":0.589406,"width":0.8584149999999999,"height":0.04749700000000001}},{"text":"Bio-Rad Laboratories, Invitrogen, and GE Healthcare have agreed to co-develop a protein test standard for the \n large-scale study and expressed an interest in commercializing the product, van Oostrum said.","bbox":{"left":0.068334,"top":0.648725,"width":0.820441,"height":0.03264900000000004}},{"text":"Officials from GE Healthcare and Bio-Rad could not be reached for confirmation or for comment. A spokeswoman \n for Invitrogen could not confirm the company is involved in the 2D gel project.","bbox":{"left":0.068334,"top":0.693271,"width":0.842114,"height":0.03264800000000012}},{"text":"Van Oostrum also said that the IAB would like to do a similar study in liquid chromatography-mass spectrometry, \n though he said that will be a ways off.","bbox":{"left":0.068334,"top":0.737741,"width":0.833885,"height":0.03264900000000004}},{"text":"“We have not approached the LC people because … although I don’t have hard evidence of it, we feel they are \n reluctant to do a test like that, and we have not set up a good experimental protocol for it yet,” he said.","bbox":{"left":0.068334,"top":0.782287,"width":0.821442,"height":0.03264800000000012}},{"text":"Such a test would require outside funding. The 2D gel study was paid for internally, “but that’s not something that \n could go on forever,” van Oostrum said. Funding efforts for a prospective LC-MS study, as well as other initiatives, \n will be directed at government entities.","bbox":{"left":0.068334,"top":0.826756,"width":0.845815,"height":0.04749700000000001}},{"text":"© Copyright 2007 GenomeWeb Daily News. All rights Reserved.","bbox":{"left":0.299412,"top":0.909333,"width":0.40190099999999995,"height":0.01498900000000003}},{"text":"2 of 2","bbox":{"left":0.0,"top":0.983799,"width":0.038197,"height":0.01687699999999992}},{"text":"11/29/2007 5:31 PM","bbox":{"left":0.86402,"top":0.983799,"width":0.13554899999999992,"height":0.01687699999999992}}],"images_bbox":[{"left":0.068333,"top":0.888257,"width":0.001078,"height":0.022803}],"images_bbox_not_text_overlap":[{"left":0.068333,"top":0.888257,"width":0.001078,"height":0.022803}]}